Skip to Content
Merck
All Photos(1)

Documents

A7655

Sigma-Aldrich

Atenolol

≥98% (TLC), powder, β₁-adrenoceptor antagonist

Synonym(s):

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H22N2O3
CAS Number:
29122-68-7
Molecular Weight:
266.34
EC Number:
249-451-7
MDL number:
MFCD00057645
UNSPSC Code:
12352200
PubChem Substance ID:
24277748
NACRES:
NA.77

product name

Atenolol, ≥98% (TLC), powder

Assay

≥98% (TLC)

form

powder

color

white to off-white

solubility

H2O: 0.3 mg/mL
DMSO: 18 mg/mL
ethanol: 3.4 mg/mL

originator

AstraZeneca

SMILES string

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

InChI key

METKIMKYRPQLGS-UHFFFAOYSA-N

Gene Information

human ... ADRB1(153)
rat ... Adrb1(24925)

Looking for similar products? Visit Product Comparison Guide

Application

Atenolol is a β-adrenergic blocker and used in the management of hypertension. Atenolol has antianginal and antiarrhythmic properties.

Biochem/physiol Actions

Selective β1-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic.

Features and Benefits

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Shelf-life of the solid is at least three years.

Application

Product No.
Description
Pricing

standard

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

ICI 118,551 hydrochloride ≥98% (HPLC), powder

Sigma-Aldrich

I127

ICI 118,551 hydrochloride

Carvedilol ≥98% (HPLC), solid

Sigma-Aldrich

C3993

Carvedilol

Atenolol-d7 analytical standard

Supelco

06613

Atenolol-d7

Nadolol analytical standard

Supelco

N1892

Nadolol

Ganesha Rai et al.
Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we
Hsin-Hui Chiu et al.
Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)
To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31
Ronald V Lacro et al.
American heart journal, 165(5), 828-835 (2013-04-30)
The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened
Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome
Laura M Kuyper et al.
The Canadian journal of cardiology, 30(5 Suppl), S47-S53 (2014-04-23)
Previous reviews have shown that β-blocker use for the treatment of hypertension without compelling indications was associated with increased risk of stroke in the elderly. It remains unclear whether this increased risk was driven by the type of β-blocker. We
View All Related Papers

Chromatograms

application for HPLC

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service